Acute myeloid leukemia patients

Ulmer, T., Schuler, U.S., Thiede, C., et al. (2002) MDRl gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62, 4955-4962. 

Pagano L, Fianchi L, Caira M, Rutella S, Leone G. (2007) The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. 

Another promising immunoconjugate is CMA-676, which is a conjugate of an anti-CD33 MoAb and cali-cheamicin, an anticancer drug shown to be 1000-fold more potent than doxorubicin in animal models. A Phase II trial of 39 acute myeloid leukemia patients resulted in 2 patients with complete remission and 7 patients who showed temporary removal of leukemia cells from the blood. CMA-676 is now in pivotol clinical studies in a number of centers in North America and Europe. ... 

Park et al. (1971) compared the effects of ascorbate on mouse plasmacytoma cells with that on normal bone marrow cells forming granulocytic colonies. Only the plasmacytoma cells responded with marked proliferation. This, however, does not imply that myeloic stem cells in general are unresponsive to ascorbate. The growth of the human promyeloic tumor cell line HL-60 was stimulated by ascorbate (Alcain et al., 1990). Similarly, bone marrow cells from a variety of acute myeloid leukemia patients responded with growth, or growth inhibition or remained unaffected (Park et al, 1992). In this context it should be stressed that inhibition of... 

Enzymes Degrading Macromolecules. Enzymes that degrade macromolecules such as membrane polysaccharides, stmctural and functional proteins, or nucleic acids, have all shown oncolytic activity. Treatment strategies include the treatment of inoperable tumors with pepsin (1) antitumor activity of carboxypeptidase (44) cytotoxicity of ribonudease (45—47) oncolytic activity of neuraminidase (48—52) therapy with neuraminidase of patients with acute myeloid leukemia (53) antitumor activity of proteases (54) and hyaluronidase treatment in the management of human soHd tumors (55). 

Moore J, Seiter K, Kolitz J et al (2006) A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 30(7) 777-783... 

HT is a 55-year-old man with newly diagnosed acute myeloid leukemia. The patient is asymptomatic at this time. Laboratory results reveal the following significant findings ... 

De Angelo, D.J. et al.. Interim analysis of a phase If study of the safety and efficacy of gemtuzumab ozogamycin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia, Proc. Am. Soc. Hem., 100,198a, Abstr. 745, 2002. 

Hartmann U, Brummendorf TH, Balabanov S et al. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005 90 307-316. 

Over 70% of transplantations were carried out concerning lympho-granulematosis, lymphoma, and myeloma others are connected with testicular cancer, acute myeloid leukemia, solid tumors and other oncological diseases. The lethality related with transplantation (100-days lethality among the transplanted patients) was 2,3% (died 4 patients) within 5 years. At the beginning of 2006 56% of all transplanted patients did not have the signs of basic disease progression. 

Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, Clark R, Levis MJ, Small D. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 3262-3270. 

H. Other considerations Neupogen has been designated an orphan product for use in the treatment of neutropenia associated with bone marrow transplant, AIDS patients with CMV retinitis being treated with ganciclovir, severe chronic neutropenia, and acute myeloid leukemia. 

E. Therapentic response In clinical trials Leukine was safe and effective in adult patients with acute myeloid leukemia, reducing the duration of neutropenia as well as chemotherapy-associated mortality and morbidity. Leukine, administered alone or after myeloablative chemotherapy, enhances the number of circulating peripheral blood progenitor cells, allowing harvest for autologous transplantation. 

Indications Treatment of patients with CD33 positive acute myeloid leukemia (AML)... 

Relling MV, Yanishevski Y, Nemec J et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998 12 346-352. 

In June 1999, phase I clinical trials of OTI-010 were initiated in cancer patients receivingchemotherapy and HSC transplantation for the treatment of high-risk hematological malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and non-Hodgkin s lymphoma). The multicenter studies, conducted in seven US and European cancer centers, showed OTI-010 to be safe and efficacious, with 52% of patients ( 40 patients) responding positively to the therapy [327297], [495015]. 

Bhatia M, Davenport V, Cairo MS. 2007. The role of interleukin-11 to prevent chemotherapy-induced cytopenia in patients with solid tumors, lymphomas, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymph. 48 9-15. 

Bennett JM, Kaminski MS, Leonard JP, Vase JM, et al. 2005. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and Iodine I 131 tositumomab. Blood. 1052 4576-4582. 

In the brain, S100A6 is restricted to some subpopulations of neurons and astrocytes (Yamashita et al., 1999). Interestingly, S100A6 is overexpressed in astrocytes associated with the neurodegenerative lesions of amyotrophic lateral sclerosis (ALS) (Hoyaux et al., 2002) as well as in patients with Alzheimer s disease (AD), and in two different AD mouse models (Boom et al., 2004). A deregulation of S100A6 expression was also found in certain tumour tissues (Stulik et al., 2000 Luu et al., 2005 Hancq et al., 2004b Cross et al., 2005) and in patients with acute myeloid leukemia (Murphy et al., 1988). 

Idarubicin is a semisynthetic anthracycline glycoside analog of daunorubicin and is approved for use in combination with cytarabine for induction therapy of acute myeloid leukemia. When combined with cytarabine, idarubicin appears to be more active than daunorubicin in producing complete remissions and in improving survival in patients with acute myelogenous leukemia. 

Illmer et al. (154) Acute myeloid leukemia 405 patients Overall survival Higher in TTC... 

---